CALGARY, Feb. 6 /PRNewswire-FirstCall/ – Dr. Brad Thompson, President and
CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as
an invited speaker as part of a panel discussion entitled “Breaking Down the
Barriers to New Neuro-Oncology Drugs” at the 10th Annual Bio CEO & Investor
Conference 2008 on Monday, February 11 at 9:30 a.m. (ET). The conference,
which is expected to draw more than 1,000 biotechnology and life sciences
investors, will be held at the Waldorf-Astoria Hotel in New York City on
February 11-13, 2008.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics’
clinical program includes a variety of Phase I and Phase II human trials using
REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
The presentation time is subject to change. This release and the
presentation related thereto contain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company’s control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general
changes to the economic environment. Investors should consult the Company’s
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to
update these forward-looking statements.
SOURCE Oncolytics Biotech Inc.
Released February 6, 2008